Gene symbol | TERT | Synonyms | CMM9, DKCA2, DKCB4, EST2, PFBMFT1, TCS1, TP2, TRT, hEST2, hTRT | Type of gene | protein-coding |
Chromosome | 5 | Map location | 5p15.33 | dbXrefs | |
Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
Description | telomerase reverse transcriptase |
GTO ID | GTC3969 |
Trial ID | NCT02293850 |
Disease | Hepatocellular Carcinoma |
Altered gene | E1A|E1B|TERT |
Therapeutic/Target gene | Therapeutic gene |
Therapy | DNA oncolytic virus |
Treatment | Telomelysin|OBP-301 |
Phase | Phase1 |
Recruitment status | Unknown |
Title | A Phase I Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma |
Year | 2014 |
Country | Korea,Republic of|Taiwan |
Company sponsor | Oncolys BioPharma Inc |
Other ID(s) | CT-OT-21 |
Vector information | |||||||||||||
|
Cohort1: dose level 1 | |||||||||
|
|||||||||
Cohort2: dose level 2 | |||||||||
|
|||||||||
Cohort3: dose level 3 | |||||||||
|